Author: admin

The Brenda O’Brien Team Achieves Remarkable Milestone: Surpasses $700,000,000 in Closed Sales

Oro Valley – Jan 15, 2024 – The Brenda O’Brien Team, distinguished real estate agents in Oro Valley AZ, proudly announces a significant achievement in their illustrious career. The team has successfully crossed over Seven Hundred Million in closed sales, showcasing their unwavering dedication and expertise in the dynamic real estate market.

Known for their commitment to excellence and client satisfaction, the Brenda O’Brien Team has become a driving force in the Oro Valley Arizona real estate landscape. This remarkable milestone underscores their proficiency in navigating the complexities of the market and delivering exceptional results for their clients.

One key factor contributing to the team’s success is their strategic affiliation with Long Realty, the foremost Real Estate Agency in southern Arizona. By aligning themselves with a market leader, the Brenda O’Brien Team, Realtors in Oro Valley AZ, has positioned themselves as the go-to choice for individuals seeking unparalleled real estate services in Oro Valley and beyond.

With a proven track record of success, the Brenda O’Brien Team has earned a reputation for professionalism, integrity, and a results-driven approach. Whether buying or selling, clients can trust that they are in capable hands with the Brenda O’Brien Team.

“As we celebrate this remarkable achievement, we want to express our gratitude to our clients, partners, and the Oro Valley community for their trust and support. Surpassing $700,000,000 in closed sales is a testament to the hard work and dedication of our team,” said Brenda O’Brien, The team leader, trainer, & driving force of the Brenda O’Brien team.

The Brenda O’Brien Team remains committed to providing top-tier real estate services, helping clients achieve their property goals with confidence. As they continue to set new benchmarks in the industry, the team looks forward to assisting more individuals and families in making informed and rewarding real estate decisions.

For inquiries, please contact: Brenda O’Brien at 520-906-2897. Brenda@BrendaOBrienTeam.com | www.BrendaOBrienTeam.com

About The Brenda O’Brien Team:

The Brenda O’Brien Team is a distinguished real estate group based in Oro Valley, known for their exceptional service, market expertise, and commitment to client success. With a focus on delivering outstanding results, the team has become a trusted name in the Oro Valley real estate landscape.

Media Contact
Company Name: Brenda O’Brien Team
Contact Person: Brenda O’Brien
Email: Send Email
Country: United States
Website: brendaobrienteam.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Brenda O\’Brien Team Achieves Remarkable Milestone: Surpasses $700,000,000 in Closed Sales

Wanglaoji Herbal Drink: Blending Tradition with Global Innovation

Over the past few days, Wanglaoji, a famous herbal beverage brand with a history dating back to 1828, held a two-day tasting event at the County Fair Building in Golden Gate Park, San Francisco. This special herbal drink, famous for its distinct herbal scent, quickly won over many local residents. “Wanglaoji is my new obsession! The herbal tea tasting was like a flavor explosion, can’t get enough!” exclaimed one of the visitors.

  

*Wanglaoji tasting event in Golden Gate Park

 Almost two centuries ago, the Wanglaoji brand was created as a prevention for excessive internal heat, and its unique formula was certified by the National Intangible Cultural Heritage. It is considered the pioneer and protector of the herbal drink tradition. The Chinese character (jí) in Wanglaoji means “auspicious” and “good fortune.” As a result, during celebrations and gatherings with loved ones, Wanglaoji has become a symbol of good wishes, cherished by all.

 Today, Wanglaoji has evolved into a well-known herbal drink suitable for people of all ages, becoming one the most popular drinks in China. From 2020 to 2022, Wanglaoji held the title of the top-selling natural herbal drink globally for three consecutive years [1].

 On October 30, 2023, Wanglaoji officially unveiled its international brand name, WALOVI, marking another significant milestone for this Asian herbal beverage on its journey towards global recognition and introducing a refreshed Wanglaoji to the world.

 With the growing global health market, Wanglaoji has adopted a culture-driven sales and marketing strategy to expand its international presence. As early as 1925, Wanglaoji participated in the London Exhibition, becaming one of the first Chinese brands to go global. In November 2019, at the Fortune Global Tech Forum, Wanglaoji collaborated with Swiss SGS and the World Federation of Chinese Medicine Societies to release the world’s first “International Standard for Herbal Tea Beverages.” 

 Currently, Wanglaoji has registered trademarks and sells its products in over 100 countries, with a sales network that covers over ten million retail outlets worldwide. Its presence in the Chinese-American market has reached 90%, and it is available on online platforms like Amazon and in local popular retailers like Costco. In 2018, the Wanglaoji Herbal Tea Museum was inaugurated in New York, and shortly afterward, another museum on Fifth Avenue in New York City was finalized and opened to the public. Wanglaoji plans to build herbal tea museums in 56 cities worldwide, sharing the rich history of herbal tea culture with different parts of the world and spreading the auspicious culture globally.

*Wanglaoji Herbal Tea Museum on Fifth Avenue in New York City

In today’s market, consumers prioritize ingredients, nutritional benefits, flavor, and texture when selecting drinks. Wanglaoji, a brand with a history of over a century, closely observes the preferences of consumers worldwide and continuously innovates in response to market changes. When it comes to product development and innovation, Wanglaoji is committed to the trend of healthy and natural plant drinks, actively expanding its product matrix. It has introduced 18 different types of herbal drinks, including sugar-free herbal drink, sparkling herbal drink, and even durian flavored herbal drink, providing consumers worldwide with more options for healthy drinks and rejuvenating the conventional image of heritage brands to draw the interest of younger generations.

https://www.xhby.net/content/s65850365e4b06716776921f0.html

https://baijiahao.baidu.com/s?id=1782171252893437409&wfr=spider&for=pc

[1] Footnote: Frost & Sullivan. Based on global annual sales of RTD natural herbal drinks in 2020, 2021 and 2022 (310ml capacity per can). Market research completed in September 2023.

 

Media Contact
Company Name: Guangzhou Wanglaoji Great Health Industry Co.,Ltd.
Contact Person: Rainie Zeng
Email: Send Email
City: Guangzhou
Country: China
Website: https://www.wljhealth.com/

Discover the Riveting Untold Backstory Behind the US Recognition of Jerusalem as Israel’s Capital in “Because It’s Just and Right”

Discover the Riveting Untold Backstory Behind the US Recognition of Jerusalem as Israel’s Capital in "Because It’s Just and Right"

15 Jan, 2024 – In an engaging new book, “Because It’s Just and Right: The Untold Back-Story of the US Recognition of Jerusalem as the Capital of Israel and Moving the US Embassy to Jerusalem,” authors Leonard Grunstein and Farley Weiss unravel the captivating political drama that led to the historic decision to recognize Jerusalem as the eternal capital of Israel and relocate the US embassy to this sacred city.

This meticulously researched book delves deep into the journey of the Jerusalem Embassy Act of 1995, from its inception by Senator Jon Kyl to its bipartisan passage by an overwhelming majority of Congress. “Because It’s Just and Right” offers readers an enlightening and entertaining exploration of how international and US law, the Bible, Jewish history, and legal precedents converged to shape this momentous decision.

Notable figures such as David Friedman, former US Ambassador to Israel, and Senator Joe Lieberman, who played a pivotal role in securing bipartisan support for the Act, have praised the book. Governor Mike Huckabee and Professor Alan Dershowitz have also lauded its significance.

Senator John Kyl provides a compelling foreword, setting the stage for a narrative that uncovers the long and arduous process spanning two decades that ultimately culminated in the embassy’s move to Jerusalem in 2018.

“Because It’s Just and Right” is essential for anyone seeking a comprehensive understanding of why Jerusalem stands as the undivided, eternal capital of the Jewish State. This book sheds light on a crucial aspect of the Israeli-Palestinian conflict that has been overlooked for far too long.

The “Top Story” podcast, hosted by JNS editor-in-chief Jonathan Tobin, offers a riveting exploration of key events and issues in the political landscape. In a recent episode, to discuss their compelling book “Because It’s Just and Right,” authors Leonard Grunstein and Farley Weiss take center stage to delve into the captivating backstory of the US recognition of Jerusalem as Israel’s capital and the relocation of the US embassy to this sacred city. With insightful discussions on historical, legal, and biblical perspectives, this podcast provides a unique and thought-provoking lens through which listeners can better understand the intricate dynamics shaping US-Israel relations and the broader Middle East. It’s a must-listen for those seeking informed and engaging analysis of significant geopolitical developments.

In this era of shifting geopolitical dynamics and renewed attention on the Middle East, “Because It’s Just and Right” offers a timely and relevant perspective on the significance of Jerusalem in the ongoing narrative of US-Israel relations.

“Because It’s Just and Right: The Untold Back-Story of the US Recognition of Jerusalem as the Capital of Israel and Moving the US Embassy to Jerusalem” is available now at major bookstores and online retailers. Don’t miss your chance to uncover the riveting backstory that reshaped history. Get your copy today!

About the Author

Leonard Grunstein is a retired attorney and banker. He founded and served as Chairman of Metropolitan National Bank and then Israel Discount Bank of NY. He’s also a founder of Project Ezrah and Beit Midrash of Teaneck, serving as its chairman.

Farley Weiss is the Past President of the National Council of Young Israel and Past President of Young. Israel of Phoenix. Chairman of the Board of the Israel Heritage Foundation. President of the Intellectual Property Law Firm of Weiss & Moy.

Book Name: Because It’s Just and Right: The Untold Back-Story of the US Recognition of Jerusalem as the Capital of Israel and Moving the US Embassy to Jerusalem
Author Name: Farley Weiss and Leonard Grunstein
ISBN Number: 1916707432
Ebook Version: Click Here
Paperback Version: Click Here
Authors Website: Click Here

Media Contact
Company Name: Amazon Publishing Company
Email: Send Email
Phone: +1-877-311-2129
Country: United States
Website: https://amzpublishingcompany.com/

From Naples to the World: Revolutionizing Remote Work With TripLeader Academy and Feel.Travel

Explore the remarkable story of Nico Estinto, a pioneer of coworking trips in Europe. From a digital marketing manager in Naples to a trailblazer in the coworking trip industry, Nico launched TripLeader Academy and soon the innovative Feel.Travel platform, reshaping the digital nomad landscape.

In the vibrant streets of Naples, a city celebrated for its culinary delights and spirited culture, Nico Estinto, a digital marketing manager, embarked on an extraordinary journey. This wasn’t just a shift in geography; it was a profound transformation of lifestyle and work. Estinto’s story is a tapestry of adventure, resilience, and a relentless pursuit of a life less ordinary, a narrative that promises to inspire anyone dreaming of breaking the mold.

From the confines of a home office, where he once orchestrated projects for international startups, Estinto’s life took a dramatic turn. Faced with a moment that shook his very foundations, he was struck by a stark realization: the fragility and unpredictability of life. “TODAY YOU ARE HERE, TOMORROW YOU DON’T KNOW,” a mantra that became the catalyst for his journey of self-discovery and reinvention. This story is not just about change; it’s about a radical reimagining of what it means to work and live, an odyssey from the familiar streets of Naples to the unknown corners of the world.

Reflecting on his enriching Erasmus experience in Malaga, Spain, Estinto chose to leave routine behind. His transition from a conventional remote worker to a digital nomad visionary started with an innovative concept: coworking trips. As one of the pioneers of this concept in Europe, his first venture in Sicily was a defining moment. Despite challenging weather conditions, a group of strangers found themselves bonding deeply, highlighting the power of shared experiences and community.

Over four years, Estinto’s digital nomad journey has seen remarkable growth. He has successfully organized over 25 coworking trips, uniting approximately 300 remote workers. Each trip has demonstrated the increasing demand for such experiences and their transformative impact.

With a community exceeding 10,000 members, Estinto established TripLeader Academy. This platform transcends being merely a training ground; it is a comprehensive environment empowering individuals to plan, sell, and host coworking trips, embodying Estinto’s vision of spreading the joy of travel and community.

In parallel, Estinto’s venture, Coworking with Nico, is evolving into Feel.Travel. This upcoming platform, designed for digital nomads, offers unique features tailored to their needs. Feel.Travel aims to create a global community of individuals passionate about exploration and remote work.

Estinto’s journey is marked by resilience, innovation, and a relentless pursuit of happiness. It is a story of not just traveling to new destinations but creating a life enriched with experiences and connections. This narrative inspires and empowers, showing that passion and determination can turn dreams into reality.

Estinto often reflects on the importance of living life to the fullest, rejecting procrastination and traditional structures in favor of creating joyful moments every day.

For individuals seeking to break away from the mundane and explore the world while working remotely, Estinto’s story serves as a source of inspiration. It reminds everyone that the world offers more than just places to visit; it is a space to connect, grow, and thrive. Estinto’s journey invites people to experience the world not just as tourists but as members of a vibrant, global community of digital nomads.

Those interested in embarking on their own journey of discovery and connection are encouraged to visit TripLeader Academy, where they can learn to plan, sell, and host coworking trips. Alternatively, they can explore Coworking with Nico to join Nico Estinto on his next adventure and become part of a growing community of digital nomads. The path to a life of joy, purpose, and global connections begins with these steps.

Media Contact
Company Name: TRIPLEADER ACADEMY
Contact Person: Nicola Estinto
Email: Send Email
Country: Cyprus
Website: https://www.coworkingwithnico.com/

Inks and Bindings To Illuminate 2024 Los Angeles Times Festival of Books

Promising self-publishing company joins the nation’s biggest literary extravaganza weekend

A literary spectacle awaits as Inks and Bindings, a trailblazing self-publishing force, will take center stage at the upcoming 29th annual Los Angeles Times Festival of Books on April 20 and 21, 2024. 

This exciting collaboration unfolds in a city pulsating with creativity, where Inks and Bindings has crafted a niche for amplifying diverse voices and elevating independent authors, bringing their unique narratives to the forefront.

The Los Angeles Times Festival of Books, the nation’s ‘largest literary event’, draws over 155,000 readers from across the nation and beyond. Since 1996, it has been a beacon for literature enthusiasts, hosting the world’s best authors, experts, poets, and musicians for a weekend dedicated to celebrating the art of storytelling.

Attendees can anticipate a literary feast spanning genres and emotions, with Inks and Bindings offering a carefully curated selection of titles that promise to captivate readers. Booth visitors will also be treated to a complimentary book catalog featuring hand-picked gems, providing an enticing glimpse into the world of independent storytelling.

As a token of appreciation to festival-goers, Inks and Bindings will also be gifting exclusive literary treasures, enhancing the overall reading experience. The booth will be a hive of activity with scheduled book signings, providing attendees with the opportunity to engage directly with published authors and secure free personalized copies of their favorite works. It’s a unique opportunity to own a piece of the Festival of Books experience.

Held at the iconic University of Southern California campus in downtown L.A., the Festival of Books has been a literary tradition since its inception. This year, the festival promises a return to the immersive, in-person experience, featuring one-on-one conversations, engaging panels, readings by beloved authors, musical performances, and much more.

All outdoor events are free to attend, and while indoor panels require a small fee for advance reservations, the enriching experience is worth every penny. Festival-goers can explore the University Park neighborhood and enjoy attractions like the California Science Center, the Natural History Museum, the Exposition Rose Garden, and the California African American Museum.

Inks and Bindings welcomes one and all to join the literary revelry at the 2024 Los Angeles Times Festival of Books. They will soon announce their booth number, and interested participants are encouraged to stay tuned by following the company’s Facebook, Instagram, and YouTube accounts.

Discover the captivating world of independent storytelling with Inks and Bindings, the gateway to diverse narratives and compelling voices. For more information, visit https://inksandbindings.com/

About Inks & Bindings: 

Launching brilliant stars into the spotlight! Inks & Bindings is set to broaden horizons, revamp to perfection, and produce a masterpiece through the power of books. 

Inks and Bindings is a premier self-publishing company located at the heart of the Golden State. Aptly based where fashion, entertainment, and culture thrive, the team goes all out in bringing independent authors into the sweet California spotlight.

Media Contact
Company Name: Inks & Bindings
Contact Person: Sally Edwards
Email: Send Email
Phone: 7142022464
Country: United States
Website: https://inksandbindings.com/

Internationally Renowned Business Architecture Target Operating Model Expert Antonia Gimenez, aka The Business Architect, Pivots Global Organizations to Success

Gimenez delivers transformational consulting designed to yield unwavering growth via business model evolution, digital and technological adaptation, and strategies for enhancing overall performance

Antonia Gimenez, the powerhouse business pioneer who consistently navigates organizations through multi-million dollar strategies for success, is transforming the business landscape with her novel approach to business architecture and target operating models (TOM).

Gimenez is known by her peers and clients as The Architect of Business® and has flexed her expertise as a lead business architect TOM expert to render an exemplary track record spanning two decades. She has earned a reputation as the best in her field for the execution of strategies that have been curated and developed solely on her own. Her skills are especially beneficial now, at a time when global economies continue to shift in response to recession. As the economy evolves and other factors ensue – technological disruptors, customer demands, competition, and more – Gimenez is steering organizations towards success with her mastermind approach.

Clients are tapping into consulting and speaking engagement opportunities via The Architect of Business®, but Gimenez also offers global disruptive management as part of her newly minted business, ecosysBiz®. 

ecosysBiz® emphasizes strategy-based solutions for all industries, including financial services, fintech and ecosystems, telecom, and more. Clients can access strategy and innovation consulting, strategy and ops model transformation, risk and regulatory consulting, tech transformation and digitalization, cyber security, and alliances with tech and data providers varying from open source to blockchain. Whether companies are interested in making a transition to the cloud, better use data to their advantage, get the most from their business model, or ensure compliance across the board, Gimenez and  ecosysBiz® provide everything needed to reach and exceed these goals.

“Our purpose is to bring certainty to businesses that boost sustainable growth worldwide,” said Gimenez. With headquarters in New York City and London, Gimenez flawlessly provides her innovative, comprehensive strategies and expertise to clients around the world. Learn more now by visiting https://antoniagimenez.com/ and https://theecosysbiz.com/.

ABOUT ANTONIA GIMENEZ

International business disruptor Antonia Gimenez is an bestselling author and founder/visionary behind The Architect of Business® and ecosysBiz®. Follow her on social media: 

LinkedIn: https://www.linkedin.com/in/antonia-gimenez-b9643436/ 

Facebook: @antonia.gimenez.161

Twitter: @bizarchitecture

Instagram: @antoniagimenezauthor

Media Contact
Contact Person: Antonia Gimenez
Email: Send Email
Phone: 020 3750 9771
City: LONDON
Country: United Kingdom
Website: https://antoniagimenez.com/

Cheeky Butler Albufeira: making Hen Do dreams come true in Portugal’s Algarve

Embark on an unforgettable journey in the Algarve with Cheeky Butler Albufeira, where hen do dreams become a reality. Discover the magic of Portugal’s stunning coastal gem as you celebrate in style.

Albufeira, Portugal – In the heart of Portugal’s stunning Algarve region, Cheeky Butler Albufeira is redefining the hen do celebration with its electrifying boat party in Albufeira.

These sizzling offerings are not just parties; they are full-fledged extravaganzas on the crystal blue waters of the Atlantic. As a top-notch party planner renowned for its creativity and attention to detail, Cheeky Butler Albufeira is dialing up the excitement for brides-to-be and their entourages from the UK.

They promise an unmatched experience, combining the thrill of a boat party in Albufeira with the breathtaking beauty of the Algarve, ensuring each celebration is an unforgettable bash in one of Europe’s most sought-after party destinations.

With its scenic coastlines and vibrant atmosphere, Albufeira is the perfect setting for the ultimate boat party. Cheeky Butler Albufeira taps into this lively spirit, offering a range of bespoke boat parties that cater to all tastes and preferences. Whether it’s cruising along the picturesque shores, dancing to the beat of the music under the sun, or enjoying a tranquil sunset on the water, these boat parties are tailor-made to deliver excitement, luxury, and unforgettable moments.

Cheeky Butler Albufeira is committed to making every hen do a unique celebration, filled with fun, laughter, and the best that Albufeira has to offer.

Private Boat Hire Albufeira – Starting at Only £55 per Person

Get ready for a two-hour private boat party like no other. Sail from Vilamoura to the mesmerizing Xirino Caves, sipping on unlimited sangria, vodka, wine, and soft drinks. The party can accommodate groups from 12 to 120 people, with sunset options available from June to September. This package includes return minibus transfers from your accommodation and, for an extra £180, the option to have a Cheeky Butler onboard to keep the party lively.

Privato Boat Party – Starting at Only £70 per Person

Elevate your hen do with a three-hour cruise featuring an open bar. Departing at 10AM, 2PM, or 5PM for a sunset experience, this half-day cruise offers the perfect blend of luxury and fun. The package caters to groups of 12 to 120 and includes return transfers from your accommodation.

Private Boat Party – Starting at Just £99 per Person

For the ultimate hen do experience, opt for a full-day private boat party. Embark on a five-hour journey to Xirino Caves Beach, complete with an open bar and a beach lunch. The party can accommodate groups as large as 120 and includes return transfers. The highlight? A stop at a captain-chosen beach for lunch and beachside fun.

Departing from Marina de Albufeira, Cheeky Butler Albufeira’s boat parties offer more than just a cruise; they promise an immersive experience that combines the beauty of the Algarve with top-notch entertainment.

So, why choose the Algarve for your hen do? With its breathtaking beaches, vibrant nightlife, and beautiful scenery, the Algarve is a paradise for party-goers and beach lovers alike. Cheeky Butler Albufeira takes this natural splendor and adds a dash of luxury, excitement, and cheeky fun, ensuring your hen do is not just a party but an epic adventure.

Ready to make waves on your hen do? Contact Cheeky Butler Albufeira and let the Algarve adventure begin!

About Cheeky Butler Albufeira

Cheeky Butler Albufeira isn’t just about planning parties; it’s about creating lifetime memories. Specializing in unforgettable hen do experiences in the Algarve, this dynamic company perfectly blends fun, luxury, and exclusivity to deliver events that are as unique as they are exhilarating. At Cheeky Butler Albufeira, every party is more than an event – it’s a tailor-made adventure crafted to fit the bride-to-be’s wildest dreams.

With an unwavering commitment to excellence and a keen eye for detail, Cheeky Butler Albufeira transforms the stunning backdrop of the Algarve into a playground of endless possibilities. Whether it’s a sun-kissed day at sea aboard a luxury private boat or a cheeky soiree with a personal butler to add a hint of spice, every experience is designed to delight and surprise.

The Algarve, with its golden beaches, crystal-clear waters, and vibrant nightlife, provides the perfect canvas for Cheeky Butler Albufeira’s masterpieces. From intimate gatherings to grandiose fiestas, our team ensures every moment is filled with laughter, joy, and celebration. We understand that a hen do is not just a party – it’s a milestone. That’s why we go above and beyond to create experiences that resonate long after the last toast is made.

Choosing Cheeky Butler Albufeira means choosing a partner who listens, innovates, and excels. We invite you to embark on a journey where your desires are our commands, and where each celebration is an echo of the Algarve’s enchanting allure. Let us turn your hen do fantasy into a dazzling reality, and show you why the Algarve is the ultimate destination for an extraordinary celebration.

Media Contact
Company Name: Cheeky Butler Albufeira
Contact Person: J.M. Bajo Amaya
Email: Send Email
Phone: +34 615 96 36 36
Country: United Kingdom
Website: https://www.cheekybutleralbufeira.co.uk/

Nigerian American Businessman Samuel Odunukan Makes Strides in Wholesale Automotive Industry

Samuel Olanrewaju Odunukan is a Nigerian American business man. He migrated to the USA in the year 2017 as a transfer student from University Of Lagos to Manchester University to earn is Bsc, he also earned a compliance degree at Zurich University in 2020.

He has worked in many business sectors such as the Wholesale Automotive, Consumer Services, Oil & Energy, Higher Education, and Food & Beverages.

He has been seen doing greater things with the public and most recently he launched his long term business goal in having a car dealership in the heart of Chicago, Illinois USA, the company goes by Lagos Motors Group. Having previously sold more than 1000 units of cars and still counting to consumers working with different car dealerships all around Chicago Illinois and independently. The long term goal is to compete with the likes of Carvana & Carmax in terms of global sales.

At Scout & Cellar Samuel is helping and advancing their mission to become carbon-neutral by 2028 and a household name by 2030, Currently he sells all over the USA as a Senior Independent Consultant with Scout & Cellar. With Over $3 Billion Dollars in investment, shipping & E Commerce. Scout & Cellar was also featured in Forbes.

He was lucky enough to be awarded three employee of the year by 3 different car dealerships, the first was with Webb Chevrolet, and the other 2 was with Jidd Motors Mitsubishi & Volume Car dealer in Naperville, Illinois. Turns out it was all a company record.

He sold his first car at Webb Chevrolet in Oak Lawn Illinois, and he was a young and aspiring sales man, was also the first out of 4 top sales associate. This made him a prominent worker and he got promoted quickly, until he earned a transfer to Jidd Motors Mitsubishi and Volume Cars Of Naperville Illinois. Over at the new dealership he sold lots of cars throughout the Chicago Land and also to all the states of the USA via online car purchase. After completing his works at Jidd Motors Mitsubishi and Volume Cars, it was then he ventured into his car business.

Media Contact
Company Name: Lagos Motors Group
Contact Person: Samuel Olanrewaju Odunukan
Email: Send Email
Country: Nigeria
Website: https://www.lagosmotorsgroup.com/

Follicular Lymphoma Market Forecasts by DelveInsight Signal Groundbreaking Growth by 2032 | Incyte, Genmab, BeiGene, Merck, ADC Therapeutics, MEI Pharma, Xynomic Pharmaceuticals, Nordic Nanovector

“Delveinsight Business Research LLP”
As per DelveInsight, the Follicular Lymphoma Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Follicular Lymphoma and the launch of new therapies in the market.

DelveInsight’s “Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Follicular Lymphoma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Follicular Lymphoma drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Follicular Lymphoma treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Follicular Lymphoma: An Overview

As per the Leukemia & Lymphoma Society, Non-Hodgkin Lymphoma (NHL) is a type of cancer that generally develops in the lymph nodes and lymphatic tissue found in organs such as the stomach, intestines, or skin. In some cases, the NHL involves bone marrow and blood. NHL is classified based on the type of lymphocyte involved: B lymphocytes (B cells), T lymphocytes (T-cells), and Natural killer cells. NHL can also be indolent (slow progression) or aggressive (rapid progression).

According to Lymphoma Research Foundation, Follicular Lymphoma is a slow-growing or indolent form of non-Hodgkin lymphoma (NHL) that arises from B-lymphocytes. This lymphoma subtype accounts for 20–30% of all NHL cases. Follicular lymphoma is usually a slow-growing (indolent) lymphoma, although some follicular lymphoma can grow rapidly.

Often patients at the time of diagnosis have obvious symptoms of the disease. The common symptoms of follicular lymphoma include enlargement of the lymph nodes in the neck, underarms, abdomen, or groin, as well as fatigue, shortness of breath, night sweats, and weight loss. If follicular lymphoma occurs in the bone marrow, it leads to anemia, thrombocytopenia, and neutropenia.

Follicular lymphoma is usually diagnosed in higher stages. The stages are divided based on the number of lymph nodes involved. Stage I: one lymph node (or lymph structure) involved; stage II: Two or more lymph nodes (or lymph structures) are involved but only on one side (above or below) of the diaphragm; stage III: lymph nodes (or structures) on both sides of the diaphragm are involved; stage IV: the lymphoma is present in the bone marrow and/or tissues or organs other than lymph nodes or lymph structures.

The treatment of follicular lymphoma is based on the severity of associated symptoms and the rate of cancer growth.

Follicular Lymphoma Market Key Facts

  • The Follicular Lymphoma market size in the seven major markets was USD 1,451 million in 2020.

  • The incident population of Follicular Lymphoma in the 7MM countries was estimated to be 35,737 cases in 2020.

  • A study conducted by Mozas et al. (2020), shows that 54% of follicular lymphoma patients were refractory or experienced relapse/progression during follow-up.

  • As per the study conducted by Smith et al. (2015), titled “Lymphoma incidence, survival and prevalence 2004–2014: subtype analyses from the UK’s Hematological Malignancy Research Network,” the incidence of follicular lymphoma was 3.23/100,000.

  • As per the study by Fujishima et al. (2018), the incidence of follicular lymphoma in Japan was 2.80 per 100,000 persons.

Follicular Lymphoma Market Growth Factors and Associated Trends

The Follicular Lymphoma market exhibits several drivers and barriers that significantly influence its growth trajectory. Drivers encompass various factors propelling market expansion, including advancements in treatment options, particularly immunotherapies and targeted therapies, which have revolutionized Follicular Lymphoma management. Additionally, the rising prevalence of Follicular Lymphoma worldwide and the increasing elderly population contribute to market growth, as this disease primarily affects older individuals. Moreover, heightened research and development initiatives and increased investments in innovative therapies further propel market progression.

However, the Follicular Lymphoma market faces several barriers that hinder its growth potential. One major challenge lies in the high cost of novel therapies, limiting accessibility for a broader patient population. Regulatory complexities and stringent approval processes also pose obstacles to the swift introduction of innovative treatments into the market. Additionally, the complexity of Follicular Lymphoma itself, characterized by diverse genetic mutations and variations in disease progression, presents challenges in developing universally effective therapies. 

Furthermore, the lack of awareness about Follicular Lymphoma among both healthcare providers and patients, leading to delayed diagnosis and treatment initiation, remains a barrier to optimizing disease management. Overcoming these barriers requires collaborative efforts among stakeholders to address cost concerns, streamline regulatory processes, advance research, and enhance awareness to ultimately improve outcomes for Follicular Lymphoma patients.

Follicular Lymphoma Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Follicular Lymphoma pipeline therapies. It also thoroughly assesses the Follicular Lymphoma market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Follicular Lymphoma drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Follicular Lymphoma Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Follicular Lymphoma epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Follicular Lymphoma epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Follicular Lymphoma Epidemiology, Segmented as –

  • Total Follicular Lymphoma Incident Cases

  • Follicular Lymphoma Risk-specific Incident Cases

  • Follicular Lymphoma Stage-specific Incident Cases

  • Follicular Lymphoma Mutation-specific Incident Cases

  • Follicular Lymphoma Refractory/Relapsed Incident Cases

  • Follicular Lymphoma Treatable Cases

Follicular Lymphoma Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Follicular Lymphoma market or expected to be launched during the study period. The analysis covers the Follicular Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Follicular Lymphoma drugs based on their sale and market share.

The report also covers the Follicular Lymphoma pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Follicular Lymphoma companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Follicular Lymphoma Market Will Evolve and Grow by 2032 @

https://www.delveinsight.com/sample-request/follicular-lymphoma-market-insights

Follicular Lymphoma Therapeutics Analysis

There are various treatment options for follicular lymphoma based on the severity of associated symptoms and the rate of cancer growth. If patients show no or very few symptoms, physicians recommend not to treat the disease right away—an approach referred to as active surveillance (“watch and wait”). The treatment of follicular lymphoma includes CAR T cell therapies, chemotherapy, radiation therapy, immunotherapy, and stem cell transplant. Patients with early-stage follicular lymphoma (Ann Arbor stages I or II) may be treated with radiation therapy alone or with radiation plus chemotherapy.

Patients with advanced disease are usually treated first with chemotherapy plus anti-CD20 antibodies, sometimes called chemoimmunotherapy. The most common antibodies used are RITUXAN (rituximab) and GAZYVA (obinutuzumab), which selectively target follicular lymphoma tumor cells. Older people without organ dysfunction can be treated with rituximab only.

In June 2020, the US FDA approved TAZVERIK (tazemetostat) for adult patients with R/R follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by the EZH2 Mutation Test; and for adult patients with R/R follicular lymphoma who have received at least two prior systemic therapies and have no satisfactory alternative treatment options.

In December 2022, the US FDA granted accelerated approval to Genentech’s LUNSUMIO (mosunetuzumab-axgb), a bispecific CD20-directed CD3 T-cell engager for adult patients with R/R follicular lymphoma after two or more lines of systemic therapy.

In November 2023, BeiGene received European Commission approval for BRUKINSA (zanubrutinib) for the treatment of R/R follicular lymphoma BRUKINSA is the first and only BTK inhibitor approved for follicular lymphoma in the European Union.

To improve the treatment scenario, Several major pharma and biotech companies are developing therapies for Follicular Lymphoma. Currently, Genmab is leading the therapeutics market with its Follicular Lymphoma drug candidates in the most advanced stage of clinical development.

Follicular Lymphoma Therapeutic Advancements and Emerging Treatments:

  • Follicular Lymphoma Clinical Trial Progression and Key Companies: The market is set to experience significant growth, driven by the progression of emerging therapies expected for launch between 2023 and 2032. Pioneering companies, including Incyte Corporation, Genmab A/S, BeiGene, Merck & Co., ADC Therapeutics, Xynomic Pharmaceuticals, Nordic Nanovector, TG Therapeutics Inc., Allogene Therapeutics, MEI Pharma, Innovent Biologics, and others, are actively engaged in developing novel drugs for potential market entry.

  • Follicular Lymphoma Emerging and Marketed Therapies: Ongoing research and development activities are fostering the introduction of innovative therapies designed to address the signs and symptoms of Follicular Lymphoma. Some of the emerging therapies in the pipeline include Tafasitamab (Incyte Corporation), Epcoritamab (Genmab A/S), Zanubrutinib (BeiGene), Pembrolizumab (Merck & Co.), and others.

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/follicular-lymphoma-market-insights

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Follicular Lymphoma Competitive Intelligence Analysis

4. Follicular Lymphoma Market Overview at a Glance

5. Follicular Lymphoma Disease Background and Overview

6. Follicular Lymphoma Patient Journey

7. Follicular Lymphoma Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Follicular Lymphoma Treatment Algorithm, Current Treatment, and Medical Practices

9. Follicular Lymphoma Unmet Needs

10. Key Endpoints of Follicular Lymphoma Treatment

11. Follicular Lymphoma Marketed Therapies

12. Follicular Lymphoma Emerging Drugs and Latest Therapeutic Advances

13. Follicular Lymphoma Seven Major Market Analysis

14. Attribute Analysis

15. Follicular Lymphoma Market Outlook (In US, EU5, and Japan)

16. Follicular Lymphoma Companies Active in the Market

17. Follicular Lymphoma Access and Reimbursement Overview

18. KOL Views on the Follicular Lymphoma Market

19. Follicular Lymphoma Market Drivers

20. Follicular Lymphoma Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/follicular-lymphoma-market-insights

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Amyloidosis Market

“Amyloidosis Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Amyloidosis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Amyloidosis market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/oncology

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Follicular Lymphoma Market Forecasts by DelveInsight Signal Groundbreaking Growth by 2032 | Incyte, Genmab, BeiGene, Merck, ADC Therapeutics, MEI Pharma, Xynomic Pharmaceuticals, Nordic Nanovector

Seborrheic Dermatitis Market to Expand at a Significant Growth Rate During the Forecast Period (2023-32) – DelveInsight | Amorepacific, Arcutis Biotherapeutics, Astion Pharma, DermBiont, MatriSysBio

“Delveinsight Business Research LLP”
As per DelveInsight, the Seborrheic Dermatitis Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Seborrheic Dermatitis and the launch of new therapies in the market.

DelveInsight’s “Seborrheic Dermatitis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Seborrheic Dermatitis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Seborrheic Dermatitis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Seborrheic Dermatitis treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Seborrheic Dermatitis: An Overview

Seborrhoeic dermatitis is a common chronic inflammatory skin condition, characterized by scaling and poorly defined erythematous patches. It may be associated with pruritus, and it primarily affects sebum-rich areas, such as the scalp, face, upper chest, and back, A milder variant is dandruff, which is manifested by dry, flaking scales on the scalp. The extent of involvement, as well as the severity of symptoms, helps to dictate treatment.

Its clinical diagnosis is based on the location and appearance of lesions. In infants, it may present as thick white or yellow greasy scales on the scalp; it is usually benign and resolves spontaneously. In adolescents and adults, Seborrhoeic dermatitis typically presents as flaky, greasy, erythematous patches on the scalp, nasolabial folds, ears, eyebrows, anterior chest, or upper back.

Treatment with antifungal agents such as topical ketoconazole is the mainstay of therapy for Seborrhoeic dermatitis of the face and body. Because of possible adverse effects, anti-inflammatory agents such as topical corticosteroids and calcineurin inhibitors should be used only for short durations.

Several over-the-counter shampoos are available for the treatment of Seborrhoeic dermatitis of the scalp, and patients should be directed to initiate therapy with one of these agents. Antifungal shampoos (long-term) and topical corticosteroids (short-term) can be used as second-line agents for the treatment of scalp Seborrhoeic dermatitis.

Seborrhoeic dermatitis typically occurs in healthy persons. Its prevalence is 1% to 3% in the general population and 34% to 83% in immunocompromised persons. It has a bimodal distribution, with peaks at 2 to 12 months of age and in adolescence and early adulthood. It is more common in men and is typically more severe in cold and dry climates and during periods of increased stress.

Seborrheic Dermatitis Market Key Facts

  • As per Berk & Scheinfeld, (2010) the prevalence of Seborrhoeic dermatitis is limited by the absence of validated diagnostic criteria as well as a grading scale of severity; however, as one of the most common skin disorders, in the US, it affects approximately 11.6% of the general population and up to 70% of infants in the first three months of life may have the condition. Among adults, the peak incidence is in the third and fourth decades of life.

  • According to Clark et al. (2015), the prevalence of seborrheic dermatitis is 1% to 3% in the general population and 34% to 83% in immune-compromised persons. It has a bimodal distribution, with peaks at two to 12 months of age and in adolescence and early adulthood.

  • As per Berl et al., the worldwide prevalence of seborrheic dermatitis is around 5%, but the prevalence of its non-inflammatory variant, dandruff, is probably closer to 50%.

Seborrheic Dermatitis Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Seborrheic Dermatitis pipeline therapies. It also thoroughly assesses the Seborrheic Dermatitis market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Seborrheic Dermatitis drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Seborrheic Dermatitis Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Seborrheic Dermatitis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Seborrheic Dermatitis epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Seborrheic Dermatitis Epidemiology, Segmented as –

  • Total Prevalent Pool of Seborrheic dermatitis in the 7MM [2019–2032]

  • Treated Prevalent Pool of Seborrheic dermatitis in the 7MM [2019–2032]

  • Gender-specific Prevalent Pool of Seborrheic dermatitis in the 7MM [2019–2032]

  • Diagnosed Prevalent Pool of Seborrheic dermatitis in the 7MM [2019–2032]

  • Age-specific Prevalent Pool of Seborrheic dermatitis in the 7MM [2019–2032]

Seborrheic Dermatitis Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Seborrheic Dermatitis market or expected to be launched during the study period. The analysis covers the Seborrheic Dermatitis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Seborrheic Dermatitis drugs based on their sale and market share.

The report also covers the Seborrheic Dermatitis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Seborrheic Dermatitis companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Seborrheic Dermatitis Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/seborrhoeic-dermatitis-market

Seborrheic Dermatitis Therapeutics Analysis

To treat this condition several alternatives are available which include calcineurin inhibitors sulfur or sulfonamide combinations, or propylene glycol. Class IV or lower corticosteroid creams, lotions, or solutions can be used for acute flares. Systemic ketoconazole or fluconazole may help if seborrheic dermatitis is severe or unresponsive. However, the use of topical steroids should be limited and appropriate for the body site to limit the risk of side effects, including epidermal and dermal atrophy, skin dyspigmentation, telangiectasia, and striae.

Pharmacologic treatment options for Seborrheic Dermatitis include antifungal preparations and anti-inflammatory agents. Antifungal preparations include selenium sulfide, pyrithione zinc, azole agents, sodium sulfacetamide, and topical terbinafine that decrease colonization by lipophilic yeast and anti-inflammatory agents including topical steroids. Creams containing antifungal and/or corticosteroid can be used for the face and trunk. Agents that help to exfoliate the   such as salicylic acid are also useful.

In the pursuit of therapeutic advancements for Seborrhoeic Dermatitis, around five notable companies are actively involved in developing treatments. Among these, Arcutis Biotherapeutics is a key player, with Seborrhoeic Dermatitis drug candidates progressing to the mid to advanced stage, Phase II clinical trials.

Seborrheic Dermatitis Companies Actively Working in the Therapeutics Market Include

  • Amorepacific

  • ArcutisBiotherapeutics

  • AstionPharmaA/S

  • CutaneaLifeSciences

  • DermBiont

  • MatriSysBio

And Many Others

Emerging and Marketed Seborrheic Dermatitis Therapies Covered in the Report Include:

  • Topical roflumilast foam (ARQ-154): Arcutis Biotherapeutics

  • Omiganan (CLS002): Cutanea Life Sciences

  • DBI-002: DermBiont

  • PAC-14028: Amorepacific

And Many More

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/seborrhoeic-dermatitis-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Seborrheic Dermatitis Competitive Intelligence Analysis

4. Seborrheic Dermatitis Market Overview at a Glance

5. Seborrheic Dermatitis Disease Background and Overview

6. Seborrheic Dermatitis Patient Journey

7. Seborrheic Dermatitis Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Seborrheic Dermatitis Treatment Algorithm, Current Treatment, and Medical Practices

9. Seborrheic Dermatitis Unmet Needs

10. Key Endpoints of Seborrheic Dermatitis Treatment

11. Seborrheic Dermatitis Marketed Therapies

12. Seborrheic Dermatitis Emerging Drugs and Latest Therapeutic Advances

13. Seborrheic Dermatitis Seven Major Market Analysis

14. Attribute Analysis

15. Seborrheic Dermatitis Market Outlook (In US, EU5, and Japan)

16. Seborrheic Dermatitis Companies Active in the Market

17. Seborrheic Dermatitis Access and Reimbursement Overview

18. KOL Views on the Seborrheic Dermatitis Market

19. Seborrheic Dermatitis Market Drivers

20. Seborrheic Dermatitis Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/seborrhoeic-dermatitis-market

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Generalized Pustular Psoriasis Market

“Generalized Pustular Psoriasis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Generalized Pustular Psoriasis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Generalized Pustular Psoriasis market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Seborrheic Dermatitis Market to Expand at a Significant Growth Rate During the Forecast Period (2023-32) – DelveInsight | Amorepacific, Arcutis Biotherapeutics, Astion Pharma, DermBiont, MatriSysBio